Drug Patent Profile
Bempedoic acid/ezetimibe - Esperion Therapeutics
At a glance
- Drug Originator Esperion Therapeutics
- Drug Licenced by CSL; Daiichi Sankyo Europe; HLS Therapeutics; Neopharm Ltd; Otsuka Pharmaceutical
- Drug Class Antihyperlipidaemics; Azetidines; Dicarboxylic acids; Fatty acids; Fluorobenzenes; Propanols; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors; Cholesterol absorption inhibitors; Cholesterol synthesis inhibitors; NPC1L1 protein inhibitors; Peroxisome proliferator-activated receptor agonists
- USA Patent Applicants ESPERION THERAPS INC
- USA Patents 31
- NDAs 1
- International Patents 73
Table of Contents

Disclaimer
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.